On November 9, 2020 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, reported new data on BT-001, a novel oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment, in the SITC (Free SITC Whitepaper) abstract "BT-001, an oncolytic vaccinia virus armed with a Tregdepleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment" (Abstract number: 594) (Press release, Transgene, NOV 9, 2020, View Source [SID1234570396]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting outlines BT-001’s unique multifunctional properties combining potent oncolytic activities with the production of high intra-tumoral concentrations of an anti-CTLA4 antibody and GM-CSF, with very low systemic exposure. It is shown that the murine surrogate mBT-001 has demonstrated outstanding antitumoral activity in several syngeneic tumor models inducing long-lasting antitumoral immune responses and abscopal effects. It concludes that BT-001 has potential for broad single agent activity-including in poorly responsive immune excluded cancers, and that selective tumor-localized delivery of anti-CTLA4 may allow for a better tolerated, sustained and more effective combination therapy with antibodies targeting the PD-1/PDL1 axis.
The poster will be available in the Virtual Poster Hall November 11-14, 2020, 9:00 a.m.-5:00 p.m. EST (3:00 – 11:00 p.m. CET). The presenting authors will answer questions on Thursday, November 12 from 4:50 to 5:20 p.m. EST (10:50 – 11:20 p.m. CET) and Saturday, November 14 from 1:00 to 1:30 p.m. EST (7:00 – 7:30 p.m. CET).
BT-001 is being co-developed by BioInvent and Transgene. It was generated using Transgene’s Invir.IO platform and its patented large-capacity VVcopTK-RR-oncolytic virus, which has been engineered to encode both a Treg-depleting anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR /F.I.R.S.T platforms, and the cytokine GM-CSF. BT-001 is expected to enter Phase I clinical development before the end of 2020. "BT-001 offers exciting potential for the treatment of cancer thanks to its unique, multiple mechanisms of action. It has been designed to combine multiple anti-cancer properties including killing of cancer cells and the production of an anti-CTLA4 antibody and GM-CSF directly at the site of the tumor, while also generating an immune response against tumor cells," said Martin Welschof, CEO of BioInvent.
Philippe Archinard, PhD, Chairman and CEO of Transgene, said: "BT-001 has induced long-lasting antitumoral immune responses and abscopal effects in tumor models, and this activity is further enhanced by a combination with anti-PD-1 treatment. We look forward to further investigating this oncolytic virus in a Phase I trial which is still expected to start before the end of the year."